Clinical Trial Update: Bendamustine/Rituximab Followed by Venetoclax and Rituximab for Treatment of Chronic Lymphocytic Leukemia [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating Bendamustine/Rituximab followed by Venetoclax and Rituximab for chronic lymphocytic leukemia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia

Drugs mentioned

• Bendamustine (Bendamustine)
• Rituximab (rituximab)
• Venetoclax (venetoclax)

Snippet

Sponsor: Nicole Lamanna | Conditions: Chronic Lymphocytic Leukemia | Phase 2 | Status: COMPLETED